# Efficacy and Safety of P1101 in Polycythemia Vera Patients for Whom the Standard of Treatment is Difficult to Apply

> **NCT04182100** · PHASE2 · COMPLETED · sponsor: **PharmaEssentia Japan K.K.** · enrollment: 29 (actual)

## Conditions studied

- Polycythemia Vera (PV)

## Interventions

- **DRUG:** P1101
- **DRUG:** Low-dose aspirin
- **PROCEDURE:** Phlebotomy

## Key facts

- **NCT ID:** NCT04182100
- **Lead sponsor:** PharmaEssentia Japan K.K.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-12-20
- **Primary completion:** 2021-03-08
- **Final completion:** 2021-03-08
- **Target enrollment:** 29 (ACTUAL)
- **Last updated:** 2025-09-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04182100

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04182100, "Efficacy and Safety of P1101 in Polycythemia Vera Patients for Whom the Standard of Treatment is Difficult to Apply". Retrieved via AI Analytics 2026-09-21 from https://api.ai-analytics.org/clinical/NCT04182100. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*